These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23256268)

  • 1. Renal transplantation from an unrelated living donor to a malignant hyperthermia-susceptible patient: a case report.
    Kern M
    AANA J; 2011 Oct; 79(5):397-400. PubMed ID: 23256268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anesthetic management of donor nephrectomy for a recipient with history of malignant hyperthermia: avoiding a transferred trigger.
    Schaff J; Maniker R
    J Clin Anesth; 2016 Jun; 31():259-62. PubMed ID: 27185722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome.
    Gross O; Weber M; Fries JW; Müller GA
    Nephrol Dial Transplant; 2009 May; 24(5):1626-30. PubMed ID: 19028755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylaxis with dantrolene sodium in 2 patients with susceptibility to malignant hyperthermia].
    Navas E; Sánchez-Peña J; Gutiérrez-Crespo A
    Rev Esp Anestesiol Reanim; 1992; 39(5):309-11. PubMed ID: 1410753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene.
    Toppin PJ; Chandy TT; Ghanekar A; Kraeva N; Beattie WS; Riazi S
    Can J Anaesth; 2010 Jul; 57(7):689-93. PubMed ID: 20431982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective genetic analysis illustrates the spectrum of autosomal Alport syndrome in a case of living-related donor kidney transplantation.
    Petzold F; Bachmann A; Bergmann C; Helmchen U; Halbritter J
    BMC Nephrol; 2019 Sep; 20(1):340. PubMed ID: 31477057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal transplantation from living donor parents in two brothers with Alport syndrome. Can asymptomatic female carriers of the Alport gene be accepted as kidney donors?
    Sessa A; Pietrucci A; Carozzi S; Torri Tarelli L; Tazzari S; Giordano F; Meroni M; Battini G; Valente U; Renieri A
    Nephron; 1995; 70(1):106-9. PubMed ID: 7617088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal transplantation in patients with Alport syndrome.
    Kashtan CE
    Pediatr Transplant; 2006 Sep; 10(6):651-7. PubMed ID: 16911486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life of living kidney donor: a national report].
    Briançon S; Germain L; Baudelot C; Bannay A; Virion JM; Thuong M
    Nephrol Ther; 2011 Jul; 7 Suppl 1():S1-39. PubMed ID: 21907160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anesthesia for patients with a history of malignant hyperthermia.
    Wappler F
    Curr Opin Anaesthesiol; 2010 Jun; 23(3):417-22. PubMed ID: 20173632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propofol anesthesia in the malignant hyperthermia susceptible patient.
    Klotz RW
    Nurse Anesth; 1991 Mar; 2(1):33-5. PubMed ID: 2021658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women with Alport syndrome: risks and rewards of kidney donation.
    Kashtan CE
    Nephrol Dial Transplant; 2009 May; 24(5):1369-70. PubMed ID: 19171688
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of intraoperative malignant hyperthermia during renal transplantation.
    Goss JA; Brennan DC; Miller BT; Shenoy S; McClure S; Howard TK; Flye MW
    Clin Transplant; 1996 Apr; 10(2):195-8. PubMed ID: 8664518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clínic of Barcelona].
    Oppenheimer F; Revuelta I; Serra N; Lozano M; Gutiérrez-Dalmau A; Esforzado N; Cofán F; Ricart MJ; Torregrosa JV; Crespo M; Paredes D; Martorell J; Alcáraz A; Campistol JM
    Nefrologia; 2010; 30(1):54-63. PubMed ID: 20038970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uneventful anaesthesia does not exclude malignant hyperthermia.
    Girard T; Urwyler A
    Acta Anaesthesiol Scand; 2008 Aug; 52(7):1027-8; author reply 1028. PubMed ID: 18702756
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fulminant malignant hyperthermia during the 6th general anesthesia using volatile anesthetics].
    Striebel HW; Lechner J; Wiegand C; Hartung E
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):475-80. PubMed ID: 1786310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant hyperthermia and the otolaryngologist.
    Chang CY; Scher RL
    Ear Nose Throat J; 2003 Jun; 82(6):433-6. PubMed ID: 12861868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Caesarean section in a patient with past history of fulminant malignant hyperthermia].
    Goto S; Ogata K; Fujie T; Fujigaki T; Nakamura H; Yukinari T; Shibata O
    Masui; 1993 Feb; 42(2):271-5. PubMed ID: 8437362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AANA Journal course: update for nurse anesthetists--genetic testing for malignant hyperthermia.
    Curtis S
    AANA J; 1996 Dec; 64(6):557-62. PubMed ID: 9204791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transient normalisation of CK blood levels in patients susceptible to malignant hyperthermia by oral administration of dantrolene (author's transl)].
    Bernhardt D
    Anaesthesist; 1982 May; 31(5):252-4. PubMed ID: 7103034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.